In a nutshell The study monitored the occurrence of possible immune-related side effects (irSEs) in patients with advanced melanoma under single and combination therapy of ipilimumab (I; Yervoy), nivolumab (N; Opdivo), and pembrolizumab (P; Keytruda). The authors found that combination therapy increases the frequency of irSEs. Some background...Read More
Current stage-Stage III Posts on Medivizor
Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?
In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...Read More
In a nutshell This study compared the effectiveness and safety of two different chemotherapies in the treatment of advanced colorectal cancer (CRC). Researchers suggested that S1-based chemotherapy is a good option for the treatment of these patients. Some background CRC is one of the most common cancers worldwide. The standard treatment is surgery...Read More
Can specialized imaging techniques improve how chemo-radiotherapy is administered in locally advanced non-small cell lung cancer?
In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients. Some background NSCLC accounts for...Read More
Do biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?
In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...Read More
In a nutshell This study investigated the role and optimal dose and duration of adjuvant (after surgery) chemotherapy (AC) in patients with locally advanced rectal cancer. Researchers suggested that this treatment was associated with improved survival in these patients. Some background Colorectal cancer is one of the most common cancers worldwide....Read More
In a nutshell This study wanted to find out which was the better treatment for advanced melanoma that has been surgically treated, ipilimumab (Yervoy) or high dose interferon alfa (HDI). The study found that low dose ipilimumab resulted in better overall survival than HDI and high dose ipilimumab, but all of the treatments had...Read More
In a nutshell This study investigated whether tummy infections (TIs) after surgery are associated with colorectal cancer outcomes. Researchers suggested that TIs might be associated with a shorter time until recurrence. Some background Colorectal cancer is a common cancer in the US affecting more than 145,000 people every year. Surgery is...Read More
In a nutshell This study wanted to find out what the best order is for treating melanoma with immunotherapy medications and surgery. The study found that immunotherapy before surgery resulted in better survival outcomes for these patients. Some background Treatments for melanoma have changed in the last few years. A newer treatment is...Read More
In a nutshell This study examined the safety and effectiveness of osimertinib (Tagrisso) compared to other targeted therapies for advanced non-small cell lung cancer (NSCLC). The authors concluded that osimertinib improved patient survival. Some background NSCLC accounts for the majority of lung cancers. Some...Read More
Durvalumab after chemoradiotherapy for non-small cell lung cancer: analysis from the patients’ perspective
In a nutshell This study evaluated the patient-reported outcomes after treatment with durvalumab (Imfinzi) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. This study concluded that durvalumab did not affect the quality of life of these patients. Some background NSCLC is the most common form of lung cancer...Read More
In a nutshell This study investigated the effects of complete mesocolic excision (CME) in patients with right-side colon cancer. Researchers suggested that CME reduces the risk of recurrences (when cancer comes back) in these patients. Some background Colorectal cancer is one of the most common cancers worldwide. The standard treatment is surgery and...Read More